Dopamine receptor downregulation: An alternative strategy for schizophrenia treatment

Medical Hypotheses

Volumn 63, Issue 6, 2004, Pages 1047-1050

  Tsai, Shih Jen ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR AFFECTING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; QUINPIROLE;

ARTICLE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; GENETIC TRANSCRIPTION; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; RNA STABILITY; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE ANTAGONISTS; DOWN-REGULATION; HUMANS; MODELS, NEUROLOGICAL; PIPERAZINES; QUINOLONES; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 7044222067     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.04.012     Document Type: Article

References (33)

1. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719
2. Wong D.F., Wagner H.N. Jr., Tune L.E., Dannals R.F., Pearlson G.D., Links J.M., et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science. 234:1986;1558-1563
3. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA. 97:2000;8104-8109
4. Reith J., Benkelfat C., Sherwin A., Yasuhara Y., Kuwabara H., Andermann F., et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. USA. 91:1994;11651-11654
5. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiat. 155:1998;761-767
6. Walinder J., Skott A., Carlsson A., Roos B.E. Potentiation by metyrosine of thioridazine effects in chronic schizophrenics A long-term trial using double-blind crossover technique. Arch. Gen. Psychiat. 33:1976;501-505
7. Bacher N.M., Lewis H.A. Addition of reserpine to antipsychotic medication in refractory chronic schizophrenic outpatients. Am. J. Psychiat. 135:1978;488-489
8. Law P.Y., Hom D.S., Loh H.H. Loss of opiate receptor activity in neuroblastoma X glioma NG108-15 hybrid cells after chronic opiate treatment. A multiple-step process. Mol. Pharmacol. 22:1982;1-4
9. Bouvier M., Collins S., O'Dowd B.F., Campbell P.T., de Blasi A., Kobilka B.K., et al. Two distinct pathways for cAMP-mediated down-regulation of the beta 2-adrenergic receptor. Phosphorylation of the receptor and regulation of its mRNA level. J. Biol. Chem. 264:1989;16786-16792
10. Gagnon A.W., Kallal L., Benovic J.L. Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the beta2-adrenergic receptor. J. Biol. Chem. 273:1998;6976-6981
11. Collins S., Bouvier M., Bolanowski M.A., Caron M.G., Lefkowitz R.J. cAMP stimulates transcription of the beta2-adrenergic receptor gene in response to short-term agonist exposure. Proc. Natl. Acad. Sci. USA. 86:1989;4853-4857
12. Tholanikunnel B.G., Malbon C.C. A 20-nucleotide (A. + U)-rich element of beta2-adrenergic receptor (beta2AR) mRNA mediates binding to beta2AR-binding protein and is obligate for agonist-induced destabilization of receptor mRNA J. Biol. Chem. 272:1997;11471-11478
13. Zhang L.J., Lachowicz J.E., Sibley D.R. The D2S and D2L dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells. Mol. Pharmacol. 45:1994;878-889
14. Chen J.F., Aloyo V.J., Weiss B. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Neuroscience. 54:1993;669-680
15. Ponzio F., Cimino M., Achilli G., Lipartiti M., Perego C., Vantini G., et al. In vivo and in vitro evidence of dopaminergic system down regulation induced by chronic L-dopa. Life Sci. 34:1985;2107-2116
16. Tamminga C.A., Schaffer M.H., Smith R.C., Davis J.M. Schizophrenic symptoms improve with apomorphine. Science. 200:1978;567-568
17. Jaskiw G.E., Popli A.P. A meta-analysis of the response to chronic L-dopa in patients with schizophrenia: therapeutic and heuristic implications. Psychopharmacology. 171:2004;365-374
18. Inoue A., Seto M., Sugita S., Hide I., Hirose T., Koga N., et al. Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Brain Res. Mol. Brain Res. 55:1998;285-292
19. Inoue A., Nakata Y. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. Jpn. J. Pharmacol. 86:2001;376-380
20. Tamminga C.A., Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr. Drug Target CNS Neurol. Disord. 1:2002;141-147
21. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 28:2003;1400-1411
22. Koenig J.A., Edwardson J.M. Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol. Sci. 18:1997;276-287
23. Tsao P., Cao T., von Zastrow M. Role of endocytosis in mediating downregulation of G-protein-coupled receptors. Trends Pharmacol. Sci. 22:2001;91-96
24. Casey D.E. Tardive dyskinesia: pathophysiology and animal models. J. Clin. Psychiat. 61(Suppl 4):2000;5-9
25. Duggal H.S. Aripiprazole-induced improvement in tardive dyskinesia. Can. J. Psychiat. 48:2003;771-772
26. Itokawa M., Toru M., Ito K., Tsuga H., Kameyama K., Haga T., et al. Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells. Mol. Pharmacol. 49:1996;560-566
27. Arinami T., Itokawa M., Enguchi H., Tagaya H., Yano S., Shimizu H., et al. Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet. 343:1994;703-704
28. Willins D.L., Berry S.A., Alsayegh L., Backstrom J.R., Sanders-Bush E., Friedman L., et al. Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. Neuroscience. 91:1999;599-606
29. Jockers R., Angers S., Da Silva A., Benaroch P., Strosberg A.D., Bouvier M., et al. Beta(2)-adrenergic receptor down-regulation evidence for a pathway that does not require endocytosis. J. Biol. Chem. 274:1999;28900-28908
30. Inoue A., Miki S., Seto M., Kikuchi T., Morita S., Ueda H., et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur. J. Pharmacol. 321:1997;105-111
31. Albaladejo V., Collu R., Andre J. Down-regulation by 17 beta-estradiol of D2 dopamine receptors in the MtTF4 pituitary tumor. Endocrinology. 114:1984;2344-2348
32. Nowak G., Arnt J., Hyttel J., Svendsen O. Down-regulation of dopamine D-2, 5-HT2 receptors and beta-adrenoceptors in rat brain after prolonged treatment with a new potential antidepressant, Lu 19-005. J. Neural. Trans. 64:1985;227-238
33. Izenwasser S., Acri J.B., Kunko P.M., Shippenberg T. Repeated treatment with the selective kappa opioid agonist U-69593 produces a marked depletion of dopamine D2 receptors. Synapse. 30:1998;275-283